238 related articles for article (PubMed ID: 15383404)
1. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations.
McGuire V; Felberg A; Mills M; Ostrow KL; DiCioccio R; John EM; West DW; Whittemore AS
Am J Epidemiol; 2004 Oct; 160(7):613-8. PubMed ID: 15383404
[TBL] [Abstract][Full Text] [Related]
2. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
Modan B; Hartge P; Hirsh-Yechezkel G; Chetrit A; Lubin F; Beller U; Ben-Baruch G; Fishman A; Menczer J; Struewing JP; Tucker MA; Wacholder S;
N Engl J Med; 2001 Jul; 345(4):235-40. PubMed ID: 11474660
[TBL] [Abstract][Full Text] [Related]
3. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
[TBL] [Abstract][Full Text] [Related]
4. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis.
Modugno F; Ness RB; Allen GO; Schildkraut JM; Davis FG; Goodman MT
Am J Obstet Gynecol; 2004 Sep; 191(3):733-40. PubMed ID: 15467532
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.
Vicus D; Finch A; Rosen B; Fan I; Bradley L; Cass I; Sun P; Karlan B; McLaughlin J; Narod SA;
Gynecol Oncol; 2010 Aug; 118(2):155-9. PubMed ID: 20452659
[TBL] [Abstract][Full Text] [Related]
6. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.
Narod SA; Risch H; Moslehi R; Dørum A; Neuhausen S; Olsson H; Provencher D; Radice P; Evans G; Bishop S; Brunet JS; Ponder BA
N Engl J Med; 1998 Aug; 339(7):424-8. PubMed ID: 9700175
[TBL] [Abstract][Full Text] [Related]
7. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
8. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
Soegaard M; Kjaer SK; Cox M; Wozniak E; Høgdall E; Høgdall C; Blaakaer J; Jacobs IJ; Gayther SA; Ramus SJ
Clin Cancer Res; 2008 Jun; 14(12):3761-7. PubMed ID: 18559594
[TBL] [Abstract][Full Text] [Related]
10. Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones.
Harlow BL; Weiss NS; Roth GJ; Chu J; Daling JR
Cancer Res; 1988 Oct; 48(20):5849-52. PubMed ID: 3167840
[TBL] [Abstract][Full Text] [Related]
11. Tubal ligation and the risk of ovarian carcinoma.
Cornelison TL; Natarajan N; Piver MS; Mettlin CJ
Cancer Detect Prev; 1997; 21(1):1-6. PubMed ID: 9043756
[TBL] [Abstract][Full Text] [Related]
12. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland.
Gronwald J; Byrski T; Huzarski T; Cybulski C; Sun P; Tulman A; Narod SA; Lubinski J
Breast Cancer Res Treat; 2006 Jan; 95(2):105-9. PubMed ID: 16261399
[TBL] [Abstract][Full Text] [Related]
13. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk.
Tworoger SS; Fairfield KM; Colditz GA; Rosner BA; Hankinson SE
Am J Epidemiol; 2007 Oct; 166(8):894-901. PubMed ID: 17656616
[TBL] [Abstract][Full Text] [Related]
14. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Neuhausen SL; Lynch HT; Rosen B; Ainsworth P; Moller P; Ghadirian P; Isaacs C; Karlan B; Sun P; Narod SA
Gynecol Oncol; 2006 Jan; 100(1):83-8. PubMed ID: 16137751
[TBL] [Abstract][Full Text] [Related]
15. Reproductive and menstrual history and papillary thyroid cancer risk: the San Francisco Bay Area thyroid cancer study.
Sakoda LC; Horn-Ross PL
Cancer Epidemiol Biomarkers Prev; 2002 Jan; 11(1):51-7. PubMed ID: 11815401
[TBL] [Abstract][Full Text] [Related]
16. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Lynch HT; Klijn J; Ghadirian P; Neuhausen SL; Kim-Sing C; Foulkes WD; Moller P; Isaacs C; Domchek S; Randall S; Offit K; Tung N; Ainsworth P; Gershoni-Baruch R; Eisen A; Daly M; Karlan B; Saal HM; Couch F; Pasini B; Wagner T; Friedman E; Rennert G; Eng C; Weitzel J; Sun P; Narod SA; ; Garber J; Osborne M; Fishman D; McLennan J; McKinnon W; Merajver S; Olsson H; Provencher D; Pasche B; Evans G; Meschino WS; Lemire E; Chudley A; Rayson D; Bellati C
Breast Cancer Res Treat; 2007 Oct; 105(2):221-8. PubMed ID: 17245541
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
18. Oral contraceptive use and BRCA penetrance: a case-only study.
Pasanisi P; Hédelin G; Berrino J; Chang-Claude J; Hermann S; Steel M; Haites N; Hart J; Peled R; Gafà L; Leggio L; Traina A; Amodio R; Primic-Zakelj M; Zadnik V; Veidebaum T; Tekkel M; Berrino F
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2107-13. PubMed ID: 19549808
[TBL] [Abstract][Full Text] [Related]
19. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S
J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636
[TBL] [Abstract][Full Text] [Related]
20. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
Narod SA; Sun P; Ghadirian P; Lynch H; Isaacs C; Garber J; Weber B; Karlan B; Fishman D; Rosen B; Tung N; Neuhausen SL
Lancet; 2001 May; 357(9267):1467-70. PubMed ID: 11377596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
